Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.08 by 125 percent. This is a 400 percent increase over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $36.220 million which beat the analyst consensus estimate of $31.960 million by 13.33 percent. This is a 77.54 percent increase over sales of $20.401 million the same period last year.